Table 3 Overall survival of miRNA that target YOD1 in PAAD
From: YOD1 serves as a potential prognostic biomarker for pancreatic cancer
miRNA | Low expression | High expression | Prognose | P-value | HR |
|---|---|---|---|---|---|
hsa-mir-675 | n = 62 | n = 116 | N/A | 0.053 | 1.54 (0.99–2.4) |
hsa-mir-150 | n = 83 | n = 95 | N/A | 0.095 | 0.71 (0.47–1.06) |
hsa-mir-202 | n = 50 | n = 128 | N/A | 0.19 | 0.75 (0.49–1.16) |
hsa-mir-1468 | n = 118 | n = 60 | Favorable | 0.02 | 0.59 (0.37–0.92) |
hsa-mir-139 | n = 133 | n = 45 | Favorable | 0.0047 | 0.46 (0.26–0.8) |
hsa-mir-140 | n = 96 | n = 82 | Favorable | 0.017 | 0.6 (0.39–0.92) |
hsa-mir-218 | n = 50 | n = 128 | Favorable | 0.0038 | 0.53 (0.35–0.82) |
hsa-mir-9 | n = 119 | n = 59 | Favorable | 0.038 | 0.61 (0.39–0.98) |
hsa-mir-342 | n = 119 | n = 59 | Favorable | 0.0013 | 0.45 (0.27–0.74) |
hsa-mir-375 | n = 93 | n = 85 | Favorable | 0.012 | 0.59 (0.39–0.9) |
hsa-mir-500a | n = 84 | n = 94 | Favorable | 0.0088 | 0.58 (0.39–0.88) |
hsa-mir-433 | n = 116 | n = 62 | N/A | 0.069 | 0.66 (0.43–1.04) |